Dry Age Related Macular Degeneration
BEACON (Allergan)A 2 year, phase 2 study on the safety and efficacy of Brimonidine Posterior Segment Drug Delivery System in Patients with geography atrophy secondary to age-related macular degeneration.
PREVENT IIT (NCRVA & Genentech)A 2 year investigator initiated study on prophylactic Ranibizumab for exudative age-related macular degeneration (AMD) in vulnerable eyes with Non exudative AMD Trial.
A 1 year Phase 2 study examining a monoclonal antibody to decrease the amount of drusen in the eyes seen in people with Dry AMD with an intravenous infusion.
A 2 year Phase 2/3 study which aims to reduce the rate of Dry AMD progression with the use of an pill.